Long-term antithyroid drug therapy

xlomafota13 shared this article with you from Inoreader Long-term antithyroid drug therapy Via radioactive iodine Curr Opin Endocrinol Diabetes Obes. 2021 Jul 6. doi: 10.1097/MED.0000000000000656. Online ahead of print. ABSTRACT PURPOSE OF REVIEW: Over the last 1-2 decades, patients and physicians have preferred antithyroid drug therapy as the initial treatment of Graves' disease, rather than radioactive iodine or surgery. More recently, the concept of long-term antithyroid drug therapy (LTADT; >24 months of treatment) has also become increasingly popular. RECENT FINDINGS: Data from c ohort studies and a prospective randomized trial suggest that LTATD therapy is safe and is associated with a higher chance of remission from Graves' disease than is shorter-term therapy. Also, LTADT may be associated with better quality of life and other clinical outcomes compared to radioiodine and surgery. SUMMARY: Long-term antithyroid drug therapy is appropriate for children and young adults. This approach is a reasonable option in those who are doing well on a stable low dose of antithyroid drug therapy, and especially those who wish to avoid definitive treatment with radioactive iodine or surgery, given their inherent risks and need for lifelong hormonal replacement therapy. PMID:34231490 | DOI:10.1097/MED.0000000000000656 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.